Helmholtz Gemeinschaft


Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial

Item Type:Article
Title:Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
Creators Name:Wulf, G.G. and Altmann, B. and Ziepert, M. and D'Amore, F. and Held, G. and Greil, R. and Tournilhac, O. and Relander, T. and Viardot, A. and Wilhelm, M. and Wilhelm, C. and Pezzutto, A. and Zijlstra, J.M. and Van Den Neste, E. and Lugtenburg, P.J. and Doorduijn, J.K. and van Gelder, M. and van Imhoff, G.W. and Zettl, F. and Braulke, F. and Nickelsen, M. and Glass, B. and Rosenwald, A. and Gaulard, P. and Loeffler, M. and Pfreundschuh, M. and Schmitz, N. and Trümper, L.
Abstract:PTCL patients exhibit poor survival with existing treatments. We investigated the efficacy of CHOP combined with alemtuzumab in 116 PTCL patients age 61–80 in an open-label, randomized phase 3 trial. Alemtuzumab was given on day 1, to a total of 360 mg in 21 patients, or 120 mg in 37. Hematotoxicity was increased with A-CHOP resulting in more grade ≥3 infections (40% versus 21%) and 4 versus 1 death due to infections, respectively. CR/CRu rate was 60% for A-CHOP and 43% for CHOP, and OR rate was 72% and 66%, respectively. Three-year-EFS, PFS and OS were 27% [15%–39%], 28% [15%–40%], and 37% ([23%–50%] for A-CHOP, and 24% [12%–35%], 29% [17%–41%], and 56% [44%–69%] for CHOP, respectively, showing no significant differences. Multivariate analyses, adjusted for strata and sex confirmed these results (hazard ratio HR(EFS): 0.7 ([95% CI: 0.5–1.1]; p = 0.094), HR(PFS): 0.8 ([95% CI: 0.5–1.2]; p = 0.271), HR(OS): 1.4 ([95% CI: 0.9–2.4]; p = 0.154). The IPI score was validated, and male sex (HR(EFS) 2.5) and bulky disease (HR(EFS) 2.2) were significant risk factors for EFS, PFS, and OS. Alemtuzumab added to CHOP increased response rates, but did not improve survival due to treatment-related toxicity.
Keywords:Alemtuzumab, Antineoplastic Combined Chemotherapy Protocols, Cause of Death, Cyclophosphamide, Doxorubicin, Peripheral T-Cell Lymphoma, Medication Adherence, Prednisone, Prognosis, Survival Analysis, Treatment Outcome, Vincristine
Publisher:Nature Publishing Group
Page Range:143-155
Date:January 2021
Official Publication:https://doi.org/10.1038/s41375-020-0838-5
PubMed:View item in PubMed

Repository Staff Only: item control page

Open Access
MDC Library